Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01037699
Other study ID # 0502-C-M05-EB
Secondary ID
Status Completed
Phase Phase 3
First received December 21, 2009
Last updated December 22, 2009
Start date January 2005
Est. completion date March 2008

Study information

Verified date December 2009
Source Instituto Valenciano de Infertilidad, IVI VALENCIA
Contact n/a
Is FDA regulated No
Health authority Spain: Ministry of Health
Study type Interventional

Clinical Trial Summary

To analyse the impact on cycle outcome of LH supplementation in ovarian stimulation controlled with a GnRH antagonist in two ages groups: patients upto 35 years old, and patients aged between 36 and 39 years old.


Description:

All patients received an oral contraceptive pill with 0.030 mg of ethinyl-estradiol and 3.0 mg of drospirenone the cycle prior to ovarian stimulation. On the second day of menstruation, patients started ovarian stimulation as follows:

Patients < 36: 225 IU/day of recombinant FSH (FSH alone group) or 150 IU of rFSH and 75 IU of rLH/day (FSH+LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration.

Patients 36-39: Initial dose of 300 IU of rFSH /day (FSH alone group)) or 225 IU of rFSH and 75 IU of rLH/day (FSH + LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration.

A maximum of 3 embryos were transferred on day 3 of embryo development.


Recruitment information / eligibility

Status Completed
Enrollment 720
Est. completion date March 2008
Est. primary completion date March 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria:

- 1st-2nd IVF cycle.

- Age until 39 years old

- BMI: 18-29.9.

- Basal FSH < 12 IU/L

Exclusion Criteria:

- LH:FSH > 2 (PCO)

- Low response background (< 5 oocytes)

- Endometrioma

- Recurrent pregnancy loss

- Any preimplantational genetic diagnosis indication

- Any systemic, metabolic or endocrinological disorder.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
rFSH: Follicle Stimulating Hormone

rFSH: Follicle Stimulating Hormone

rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)

rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)


Locations

Country Name City State
Spain IVI Valencia Valencia

Sponsors (1)

Lead Sponsor Collaborator
Instituto Valenciano de Infertilidad, IVI VALENCIA

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Implantation rate 4 weeks after embryo transfer No
See also
  Status Clinical Trial Phase
Completed NCT01121991 - A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies Phase 3
Not yet recruiting NCT04539067 - Effect of Controlled Ovarian Stimulation in Quality of Oocyte and Embryo Phase 2
Recruiting NCT02715336 - Efficacy and Safety of Medication Used to Stimulate Ovulation Phase 4
Not yet recruiting NCT03298750 - Mechanical Stimulation of the Ovary for Infertility Treatment in Patients With Very Low Ovarian Reserve N/A
Completed NCT03939403 - Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor Phase 4
Recruiting NCT06142708 - The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger N/A
Recruiting NCT05166668 - Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle N/A
Completed NCT04549649 - The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response N/A
Terminated NCT01816789 - Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles Phase 4
Completed NCT00823004 - Antagonist/Letrozole in Poor Responders Phase 1/Phase 2
Not yet recruiting NCT06175832 - PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study Phase 4
Completed NCT01145144 - Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment N/A
Completed NCT00830492 - Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist Phase 4
Completed NCT00829075 - Impact of Three Different Gonadotrophin Regimes on Egg Donation Program Phase 4
Completed NCT01112358 - Lutropin Alfa in Women at Risk of Poor Response Phase 2
Recruiting NCT03400722 - Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response Phase 4
Completed NCT00669786 - Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles Phase 3